Fighting liver fibrosis to reduce mortality associated with chronic liver diseases: The importance of new molecular targets and biomarkers.
作者信息
Muriel Pablo
机构信息
Laboratory of Experimental Hepatology, Department of Pharmacology, Cinvestav-IPN, Av. Instituto Politécnico Nacional, 2508, Col. San Pedro Zacatenco, 07360, Apartado Postal 14-740, Mexico City, Mexico.
出版信息
EBioMedicine. 2019 Feb;40:35-36. doi: 10.1016/j.ebiom.2019.02.002. Epub 2019 Feb 10.
Abstract
摘要
相似文献
1
Fighting liver fibrosis to reduce mortality associated with chronic liver diseases: The importance of new molecular targets and biomarkers.
EBioMedicine. 2019 Feb;40:35-36. doi: 10.1016/j.ebiom.2019.02.002. Epub 2019 Feb 10.
2
Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues.
Mol Aspects Med. 2019 Feb;65:37-55. doi: 10.1016/j.mam.2018.09.002. Epub 2018 Sep 13.
3
The global impact of hepatic fibrosis and end-stage liver disease.
Clin Liver Dis. 2008 Nov;12(4):733-46, vii. doi: 10.1016/j.cld.2008.07.007.
4
Reversibility of hepatic fibrosis and cirrhosis--is it all hype?
Nat Clin Pract Gastroenterol Hepatol. 2007 May;4(5):236-7. doi: 10.1038/ncpgasthep0813.
5
Role of Interleukin-22 in chronic liver injury.
Cytokine. 2017 Oct;98:107-114. doi: 10.1016/j.cyto.2016.08.023. Epub 2016 Nov 2.
6
Development and Regression of Cirrhosis.
Dig Dis. 2016;34(4):374-81. doi: 10.1159/000444550. Epub 2016 May 11.
7
A mouse model of liver injury to evaluate paracrine and endocrine effects of bone marrow mesenchymal stem cells.
Methods Mol Biol. 2014;1213:69-79. doi: 10.1007/978-1-4939-1453-1_7.
8
Rating fibrosis progression in chronic liver diseases.
J Hepatol. 2003 Mar;38(3):357-60. doi: 10.1016/s0168-8278(03)00010-2.
9
[Peroral and intravenous galactose test in liver diseases: personal study].
Acta Gastroenterol Belg. 1972 Jan-Feb;35(1):7-22.
10
Hepatic fibrosis in paediatric liver disease.
Clin Res Hepatol Gastroenterol. 2012 Jun;36(3):268-70. doi: 10.1016/j.clinre.2012.03.014. Epub 2012 May 18.
引用本文的文献
1
Genome-wide DNA methylation dynamics in carbon tetrachloride-induced mice liver fibrosis.
Iran J Basic Med Sci. 2023 Jan;26(1):85-92. doi: 10.22038/IJBMS.2022.66256.14555.
2
Forsythiaside A Regulates Activation of Hepatic Stellate Cells by Inhibiting NOX4-Dependent ROS.
Oxid Med Cell Longev. 2022 Jan 5;2022:9938392. doi: 10.1155/2022/9938392. eCollection 2022.
3
Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.
Drugs. 2021 Mar;81(4):419-443. doi: 10.1007/s40265-020-01458-x.
本文引用的文献
1
Autocrine CTHRC1 activates hepatic stellate cells and promotes liver fibrosis by activating TGF-β signaling.
EBioMedicine. 2019 Feb;40:43-55. doi: 10.1016/j.ebiom.2019.01.009. Epub 2019 Jan 11.
2
Stevia rebaudiana tea prevents experimental cirrhosis via regulation of NF-κB, Nrf2, transforming growth factor beta, Smad7, and hepatic stellate cell activation.
Phytother Res. 2018 Dec;32(12):2568-2576. doi: 10.1002/ptr.6197. Epub 2018 Sep 24.
3
Naringenin prevents experimental liver fibrosis by blocking TGFβ-Smad3 and JNK-Smad3 pathways.
World J Gastroenterol. 2017 Jun 28;23(24):4354-4368. doi: 10.3748/wjg.v23.i24.4354.
4
Hepatic stellate cells as key target in liver fibrosis.
Adv Drug Deliv Rev. 2017 Nov 1;121:27-42. doi: 10.1016/j.addr.2017.05.007. Epub 2017 May 12.
5
Role of Oxidative Stress in Liver Health and Disease.
Oxid Med Cell Longev. 2016;2016:9037051. doi: 10.1155/2016/9037051. Epub 2016 Mar 22.
6
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer.
Nature. 2015 Jul 9;523(7559):177-82. doi: 10.1038/nature14581. Epub 2015 Jun 24.
7
Role of free radicals in liver diseases.
Hepatol Int. 2009 Dec;3(4):526-36. doi: 10.1007/s12072-009-9158-6. Epub 2009 Nov 26.
8
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis.
Nature. 2009 Jan 1;457(7225):102-6. doi: 10.1038/nature07623.
9
Mechanisms of TGF-beta signaling from cell membrane to the nucleus.
Cell. 2003 Jun 13;113(6):685-700. doi: 10.1016/s0092-8674(03)00432-x.
Zotero 插件